Current pain and headache reports · 2026
Phenotype-guided Management of Post-traumatic Headache: An Update on Pathophysiology and Treatment.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Díaz Paulina G, Lehman Arielle B
Аннотация
PURPOSE OF REVIEW: To provide an update on the pathophysiology, phenotyping, and management of post-traumatic headache (PTH) following mild traumatic brain injury (mTBI), and to propose a phenotype-guided framework for evaluation and treatment.
RECENT FINDINGS: Emerging evidence suggests that PTH represents a distinct pathophysiological entity rather than simply a variant of migraine. Recent studies involving calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP), autonomic dysfunction, and neuroimaging biomarkers suggest that PTH may comprise several biologically distinct subgroups rather than a single disorder. Current management increasingly emphasizes phenotype-guided treatment and multidisciplinary rehabilitation interventions. However, PTH-specific randomized trial data remain limited, and most treatment recommendations continue to be extrapolated from primary headache disorders. PTH is heterogeneous, with overlapping clinical phenotypes. Management should be individualized based on headache phenotype and patient comorbidities. Given the multifactorial pathophysiology of PTH, a multimodal approach is recommended, integrating phenotype-guided pharmacologic therapy, targeted rehabilitation, and behavioral and lifestyle interventions.
RECENT FINDINGS: Emerging evidence suggests that PTH represents a distinct pathophysiological entity rather than simply a variant of migraine. Recent studies involving calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP), autonomic dysfunction, and neuroimaging biomarkers suggest that PTH may comprise several biologically distinct subgroups rather than a single disorder. Current management increasingly emphasizes phenotype-guided treatment and multidisciplinary rehabilitation interventions. However, PTH-specific randomized trial data remain limited, and most treatment recommendations continue to be extrapolated from primary headache disorders. PTH is heterogeneous, with overlapping clinical phenotypes. Management should be individualized based on headache phenotype and patient comorbidities. Given the multifactorial pathophysiology of PTH, a multimodal approach is recommended, integrating phenotype-guided pharmacologic therapy, targeted rehabilitation, and behavioral and lifestyle interventions.